Ariz Anklesaria, DO
Psychiatry · Troy, OHNPI 1538314398
Payments from drug & device makers
Across 850 payments — averaging $111.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$33K
- Biohaven Pharmaceutical Holding Company Ltd.$33K
- Biohaven Pharmaceuticals, Inc.$12K
- Otsuka America Pharmaceutical, Inc.$4K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- Johnson & Johnson$3K
- plus $8K from 21 others
Across 1 payment — averaging $250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$250
What the payments were for
- Consulting fees$2,86716%
- Travel & lodging$2,28912%
- Food & beverage$13,08871%
- Education$1571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 9 | $32,850 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $32,654 |
| Biohaven Pharmaceuticals, Inc. | 1 | $11,800 |
| Otsuka America Pharmaceutical, Inc. | 213 | $3,583 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $2,912 |
| Johnson & Johnson | 69 | $2,685 |
| AbbVie(2 entities) | 157 | $1,691 |
| Vanda Pharmaceuticals Inc. | 69 | $1,287 |
| Axsome Therapeutics, Inc. | 51 | $1,079 |
| Alkermes, Inc. | 76 | $978 |
| Lundbeck LLC | 58 | $900 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $468 |
| Indivior Inc. | 22 | $453 |
| Teva Pharmaceuticals USA, Inc. | 15 | $351 |
| E.r. Squibb & Sons, L.L.C. | 27 | $307 |
| Neurocrine Biosciences, Inc. | 8 | $142 |
| Idorsia Pharmaceuticals US Inc | 5 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $78 |
| Pear Therapeutics (US), Inc. | 3 | $65 |
| USWM, LLC | 3 | $63 |
| Braeburn Inc. | 2 | $57 |
| Biogen | 2 | $36 |
| Noven Therapeutics, LLC | 2 | $29 |
| Luye Pharma (USA) Ltd. | 1 | $21 |
| Brainsway USA Inc | 1 | $21 |
| Tris Pharma Inc | 1 | $17 |
| Orexo US, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MYCITE$2,867
- SPRAVATO$1,318
- VRAYLAR$129
- Auvelity$122
How this compares
$94,629 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HetliozTasimelteon | 15 | $344,871 |
| SpravatoEsketamine Hcl | 29 | $64,119 |
| CaplytaLumateperone Tosylate | 24 | $38,379 |
| VraylarCariprazine Hcl | 26 | $30,393 |
| LybalviOlanzapine/Samidorphan Malate | 16 | $28,089 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $17,889 |
| TrintellixVortioxetine Hydrobromide | 29 | $13,993 |
| RexultiBrexpiprazole | 12 | $11,189 |
| FetzimaLevomilnacipran Hcl | 13 | $7,435 |
| QuviviqDaridorexant Hcl | 12 | $5,558 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 30 | $1,364 |
| Atomoxetine Hcl | 17 | $1,352 |
| Aripiprazole | 30 | $1,117 |
| Buspirone Hcl | 55 | $815 |
| Ziprasidone Hcl | 16 | $677 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Vanda Pharmaceuticals Inc.Hetlioz | $1,287 | $344,87115 claims |
| Johnson & JohnsonSpravato | $2,685 | $64,11929 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $468 | $38,37924 claims |
| AbbVieVraylar, Fetzima | $1,691 | $37,82839 claims |
| Alkermes, Inc.Lybalvi | $978 | $28,08916 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $78 | $13,99329 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $3,583 | $11,18912 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $92 | $5,55812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Troy
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
- Diab AlmhanaAvon Lake$2.7M
- Mohamed Abdel AzizWest Chester$2.6M
- Fred RomeoColumbus$2.3M
- Mark WoyshvilleMiddleburg Heights$2.2M
- Amita PatelDayton$2.1M
- Caleb AdlerCincinnati$2M
- Richard SandersDayton$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.